Follow The Filings

CGON CG Oncology Inc.

Health Care, filed as CG ONCOLOGY INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 2

  • 2 Owners
  • Max 15.9%
  • $101M
  • 1 new 1 reduce 1 exit

In 2026 Q2 David Witzke opened a position in CG Oncology, James Silverman trimmed, and Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 15.9% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke New 15.9%
  2. James Silverman Reduce 0.11%

Who owns CGON

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 15.9% New 15.9% 1,398,948 $99M History
James Silverman, Opaleye Management 0.11%, was 0.84% Reduce −81.2% 17,789 $1.3M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 0.26% Exit −0.26% 674,000 $46M History

2 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CGON's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CGON insider trades
  • $24.8M bought by 1 insider
  • None no sales outside a trading plan
  • $4.8M sold by 2 insiders under 10b5-1 plans
  1. Leonard E Post Director
    Planned sale
    $62K 1,000 shares at $62.07 100% of stake
    Traded Oct 15 Filed Oct 19
    ↗
  2. Leonard E Post Director
    Planned sale
    $73K 1,000 shares at $72.98 100% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  3. Leonard E Post Director
    Planned sale
    $75K 1,000 shares at $74.54 100% of stake
    Traded Aug 14 Filed Aug 18
    ↗
  4. Leonard E Post Director
    Planned sale
    $71K 1,000 shares at $71.17 100% of stake
    Traded Jul 15 Filed Jul 17
    ↗
  5. James Mulay Director
    Planned sale
    $1.8M 24,165 shares at $75.16 100% of stake
    Traded Jul 10 Filed Jul 14
    ↗
  6. Brian Guan-Chyun Liu Director
    Buy
    $24.8M 371,085 shares at $66.87 +25% to stake
    Traded Jun 25 Filed Jun 29
    ↗
  7. Leonard E Post Director
    Planned sale
    $350K 5,000 shares at $70.00 100% of stake
    Traded Jun 24 Filed Jun 25
    ↗
  8. Leonard E Post Director
    Planned sale
    $325K 5,000 shares at $65.00 100% of stake
    Traded Jun 22 Filed Jun 23
    ↗
  9. James Mulay Director
    Planned sale
    $118K 1,964 shares at $60.12 100% of stake
    Traded Jun 15 Filed Jun 16
    ↗
  10. Leonard E Post Director
    Planned sale
    $55K 1,000 shares at $54.50 100% of stake
    Traded Jun 4 Filed Jun 5
    ↗
  11. James Mulay Director
    Planned sale
    $1.1M 15,600 shares at $73.01 100% of stake
    Traded Apr 17 Filed Apr 20
    ↗
  12. James Mulay Director
    Planned sale
    $125K 1,964 shares at $63.50 100% of stake
    Traded Mar 16 Filed Mar 17
    ↗
  13. James Mulay Director
    Planned sale
    $585K 11,145 shares at $52.47 100% of stake
    Traded Jan 9 Filed Jan 13
    ↗
  14. Leonard E Post Director
    Planned sale
    $41K 1,000 shares at $41.43 100% of stake
    Traded Nov 17, 2025 Filed Nov 18, 2025
    ↗
  15. Leonard E Post Director
    Planned sale
    $43K 1,000 shares at $43.25 100% of stake
    Traded Oct 13, 2025 Filed Oct 15, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 18 option exercises and 2 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
424B5 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $1.14M $4.04M
Net income -$88.04M -$161M
Net margin * -7729.5% -3985.0%

Balance sheet

Metric FY2024 FY2025
Total current assets $754.21M $759.48M
Total non-current assets * $0.587M $32.12M
Total assets $754.8M $791.59M
Total current liabilities $21.37M $30.84M
Total non-current liabilities * $0.052M $8.15M
Total equity $733.38M $752.6M

Cash flow

Metric FY2024 FY2025
Cash from operations -$78.71M -$132.35M
Cash from investing -$300.76M -$245.82M
Cash from financing $628.28M $153.59M
Net change in cash $248.8M -$224.58M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.